Posts in the “Lung Cancer Drugs Lung Cancer Drugs” category:

AstraZeneca Whale Racing With Minnow to Develop Lung Cancer Drug

Posted by Samantha Powell on October 1st, 2014 |

The race to develop a new class of lung-cancer medicines is pitting one of the world’s biggest drugmakers against a five-year-old startup. AstraZeneca Plc (AZN), the U.K.’s second-largest pharmaceutical company, and Clovis Oncology Inc. (CLVS) of Boulder, Colorado, both intend to seek approval from regulators next year. Both drugs, which target a form of the… Read More

Bristol-Myers’ oncology star lines up for lung cancer approval, leading the PD-1 pack

Posted by Samantha Powell on September 29th, 2014 |

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb ($BMY) was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs. The company has completed a European application… Read More

Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac

Posted by Samantha Powell on September 17th, 2014 |

A little more than two months after inking a licensing deal with Sanofi ($SNY), CureVac has completed another tie-up, banking a $45 million upfront from Boehringer Ingelheim and partnering its therapeutic vaccine aimed at lung cancer. The deal also includes up to about $556 million in prospective milestones for the German biotech. In exchange for… Read More

FDA Approves Merck’s New-Wave Cancer Drug

Posted by Samantha Powell on September 4th, 2014 |

U.S. regulators on Thursday approved a new kind of cancer drug from Merck MRK +1.68% & Co. that is designed to unleash the body’s immune system against tumors. The drug is part of a long-anticipated wave of medicines that could transform cancer treatment and forge a large new market for pharmaceutical companies. The Food and… Read More

Powerful New Cancer Drugs Offer Hope—at Steep Cost

Posted by Samantha Powell on September 3rd, 2014 |

The first of a promising new class of cancer drugs went on sale in Japan this week at an average annual cost of $143,000 a patient, a harbinger of hefty prices the new drugs are expected to command in the U.S. and Europe in coming months. The drug Opdivo, from Ono Pharmaceutical Co. 4528.TO -2.06%… Read More

Gibbs Cancer Center selected to test new drugs for lung cancer

Posted by Samantha Powell on July 2nd, 2014 |

The Gibbs Cancer Center and Research Institute in Spartanburg has been selected as one of the first 10 sites in the world to test new drugs that target the type of lung cancer often associated with smoking. Patients who meet eligibility requirements will be administered the drugs based on a 200-gene profile, which uses biomarkers… Read More

Ambitious ‘Lung-MAP’ Trial Aims to Evaluate Biomarkers and New Drugs in Squamous Cell Lung Cancer

Posted by Samantha Powell on June 23rd, 2014 |

This month, the National Cancer Institute (NCI), along with the FDA, the Southwest Oncology Group (SWOG), several private foundations and five pharmaceutical companies, launched a prospective, biomarker-driven study of new drugs for squamous cell lung cancer. The Lung-MAP trial is remarkable for its collaborative nature, and scope. The study will identify “actionable” molecular abnormalities in… Read More

New study aims to rapidly test lung cancer drugs

Posted by Samantha Powell on June 16th, 2014 |

A bold new way to test cancer drugs started Monday in hundreds of hospitals around the U.S. In a medical version of speed dating, doctors will sort through multiple experimental drugs and match patients to the one most likely to succeed based on each person’s unique tumor gene profile. It’s a first-of-a-kind experiment that brings… Read More

A Cure for Lung Cancer? Doctors Hail Incredible Breakthrough With New Drugs

Posted by Samantha Powell on May 17th, 2014 |

Date: 5/17/14 Outlet Full Name: Daily Mail UK Author: Stephen Adams – Scientists are reporting success treating advanced lung cancer with drugs such as nivolumab – The drug helped a quarter of 129 US patients with advanced lung cancer survive two years – Nivolumab is one of a new class of drug, called anti-PD1s… Read More

Boehringer Ingelheim’s Lung Cancer Drug Ups OS in Patients With EGFR Mutations

Posted by Samantha Powell on May 15th, 2014 |

Date: 5/15/14 Outlet Full Name: Drug Discovery and Development Author: No author Boehringer Ingelheim announced new overall survival results from a post-hoc analysis combining the data of two Phase 3 trials (LUX-Lung 3 and LUX-Lung 6). The analysis showed patients with non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations… Read More